MICM分型在弥漫大B细胞淋巴瘤中的作用研究进展  

Research progress on role of MICM classification in diffuse large B-cell lymphoma

作　　者：赵凯祺 苏丽萍[2] ZHAO Kaiqi;SU Liping(Shanxi Medical University,Taiyuan 030001,China)

机构地区：[1]山西医科大学,山西太原030001 [2]山西省肿瘤医院血液科,山西太原030013

出　　处：《陕西医学杂志》2023年第9期1275-1278,共4页Shaanxi Medical Journal

基　　金：山西省卫生健康委员会科研课题(2022121)。

摘　　要：弥漫大B细胞淋巴瘤(DLBCL)是常见的淋巴造血系统恶性肿瘤之一,具有高度异质性,也是非霍奇金淋巴瘤(NHL)中最常见的病理类型。随着基因组学、诊断技术和靶向治疗的发展,淋巴瘤的诊断分型不再局限于病理形态学和免疫表型,细胞遗传学和分子生物学逐渐在其中发挥越来越重要的作用,新出现的各种生物标志物也为深入了解淋巴瘤的发生与发展机制、优化治疗及评估预后奠定了基础。形态学、免疫学、细胞遗传学和分子学分型一起构成了淋巴瘤诊疗的MICM分型。现就MICM分型在DLBCL诊断、分型、分期、治疗及预后方面的作用进行综述。Diffuse large B-cell lymphoma(DLBCL)is one of the common malignant tumors of the hematopoietic system,which is highly heterogeneous.It is also the most common pathological type of non-Hodgkin lymphoma(NHL).With the development of genomics,diagnostic technology and targeted therapy,the diagnostic classification of lymphoma is no longer limited to pathomorphology and immunophenotyping,but cytogenetics and molecular biology gradually play an increasingly important role in it.Various emerging biomarkers also lay the foundation for further understanding the mechanism of lymphoma occurrence and development,optimizing treatment and evaluating prognosis.Morphology,immunology,cytogenetics and molecular typing together constitute the MICM classification of lymphoma.This article reviews the role of MICM classification in the diagnosis,classification,staging,treatment and prognosis of DLBCL.

关 键 词：弥漫大B细胞淋巴瘤 病理形态学 免疫表型 细胞遗传学 分子生物学 MICM分型 

分 类 号：R733.1[医药卫生—肿瘤]